Antibodies for anti-viral therapy.
A German university has developed a procedure to stimulate antibodies that promote the anti-viral T cell response. Since only very few direct anti-viral therapeutics are available, the stimulation procedure is a valid alternative or additional therapeutic approach. The university offers a license agreement to pharmaceutical companies.
The university is looking for partners from the pharmaceutical industry who are interested in applying the method and is offering them a license agreement.
Cytotoxic CD8-positive T cells constitute the crucial leukocyte subpopulation for a cellular response against viral infection. Since only very few direct anti-viral therapeutics are available, the stimulation of an efficient and specific immune response against a viral infection is a valid alternative or additional therapeutic approach. The first of such strategies has been established by use of high doses of interferon, which however has a high risk of adverse reactions of the immune system, and low response rates. Therefore, it is mandatory to search for further immune stimulatory strategies that more specifically induce an anti-viral T cell response. The herein described approach of a German university is based on an antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction. The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against the influenza virus and cytomegalovirus. The monoclonal, humanized anti-CEACAM1 antibodies are offered under license agreement to partners from the pharmaceutical sector, who are interested in applying the method.
Advantages and innovations
The procedure presented here is a novelty in antibody research. For the first time a therapy approach is stimulating an immune response to a viral infection. It is conceivable as a monotherapy or in combination with other anti-viral therapies. Other advantages are: • Applies to a broad range of viruses • Specific immune response against specific viruses to biogas / methane without inhibition risks
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below